Repository Spotlight – Dr. Hervé Perron, GeNeuro

GeNeuro is an emerging Swiss biotech company that has identified a completely novel therapeutic target in MS. This target is expressed by inactive, ancestral retroviral insertions in the human genome called HERVs (human endogenous retroviral sequences), and acts to exacerbate the inflammatory process. An antibody-based drug against the novel target is currently being studied in clinical trials. ACP Repository samples are being used to develop a test to be used on clinical samples obtained in these trials with the intention of bringing a new drug to market. This study is just one of more than one hundred studies using ACP Repository samples to advance and accelerate research into MS.